Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women.

Lundkvist J, Johnell O, Cooper C, Sykes D.

Osteoporos Int. 2006 Feb;17(2):201-11. Epub 2005 Jul 19.

PMID:
16027955
2.
3.

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.

Murphy DR, Smolen LJ, Klein TM, Klein RW.

BMC Musculoskelet Disord. 2012 Oct 30;13:213. doi: 10.1186/1471-2474-13-213.

4.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
5.

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.

Ström O, Borgström F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA.

Osteoporos Int. 2007 Aug;18(8):1047-61. Epub 2007 Feb 28.

PMID:
17333449
6.

Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.

Schousboe JT, Ensrud KE, Nyman JA, Melton LJ 3rd, Kane RL.

J Am Geriatr Soc. 2005 Oct;53(10):1697-704.

PMID:
16181168
7.

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.

Hiligsmann M, Reginster JY.

Bone. 2010 Jul;47(1):34-40. doi: 10.1016/j.bone.2010.03.009. Epub 2010 Mar 18.

PMID:
20303422
8.

Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.

Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E.

Bone. 2014 Feb;59:105-13. doi: 10.1016/j.bone.2013.11.002. Epub 2013 Nov 12.

PMID:
24231131
9.

Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.

Borgström F, Ström O, Marin F, Kutahov A, Ljunggren O.

J Med Econ. 2010;13(3):381-92. doi: 10.3111/13696998.2010.499072.

PMID:
20604678
10.

An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.

Borgström F, Jönsson B, Ström O, Kanis JA.

Osteoporos Int. 2006 Dec;17(12):1781-93. Epub 2006 Sep 29.

PMID:
17009083
11.

The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks.

van Staa TP, Kanis JA, Geusens P, Boonen A, Leufkens HG, Cooper C.

Value Health. 2007 Sep-Oct;10(5):348-57.

12.

Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

Tosteson AN, Burge RT, Marshall DA, Lindsay R.

Am J Manag Care. 2008 Sep;14(9):605-15.

13.
14.
15.

Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.

Schousboe JT, Ensrud KE, Nyman JA, Kane RL, Melton LJ 3rd.

Osteoporos Int. 2005 Dec;16(12):1883-93. Epub 2005 Aug 31.

PMID:
16133649
16.

Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures.

Johnell O, Jönsson B, Jönsson L, Black D.

Pharmacoeconomics. 2003;21(5):305-14.

PMID:
12627984
17.
18.

Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.

Hiligsmann M, Reginster JY.

Pharmacoeconomics. 2011 Oct;29(10):895-911. doi: 10.2165/11539980-000000000-00000.

19.

Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.

Appl Health Econ Health Policy. 2013 Oct;11(5):485-97. doi: 10.1007/s40258-013-0047-8.

PMID:
23868102
20.

The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.

Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM.

Arch Intern Med. 2006 Jun 12;166(11):1209-17.

PMID:
16772249

Supplemental Content

Support Center